10 Stocks That Analysts Are Talking About

6. Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX)

Crinetics Pharmaceuticals Inc. is a clinical-stage pharmaceutical company committed to developing, discovering, and commercializing novel therapeutics for rare endocrine-related and endocrine disorders. The company received an upgrade from Jefferies to Buy from Hold with a repeated target price of $55.

The stock declined recently due to concerns related to atumelnant, an experimental therapy for CAH (Congenital Adrenal Hyperplasia). Even though the results were positive, analysts opine that higher expectations caused the sell-off. CRNX is trading down 23% YTD.

Taking the opportunity of the recent sell-off, Jeffries upgraded the stock. It said that the $1 billion opportunity wasn’t properly being priced in and after the sell-off, the stock is a buy. Crenessity, a CAH treatment by Neurocrine, was also launched recently but analysts believe CRNX has a very good opportunity to differentiate itself as a better product, helping its marketing efforts once its own drug is approved.